AB 2571 adds a pharmacist services benefit to the Medi‑Cal program, contingent on federal approval. The bill directs the Department of Health Care Services (DHCS) to establish a pharmacist services fee schedule and sets reimbursement rates: standard pharmacist services at 85% of the Medi‑Cal physician fee schedule, while advanced practice pharmacist services are paid at the full physician rate.
Medication therapy management (MTM) is treated specially in the statute and linked to Section 14132.969.
The measure lists covered pharmacist services (including naloxone, contraception, immunizations, tobacco cessation, PrEP/PEP, and MTM tied to specialty drugs), requires pharmacists to enroll as ordering/referring/prescribing providers before billing, and instructs DHCS to seek both federal approvals to implement the benefit and a state plan amendment to recognize pharmacists as billable providers at federally qualified health centers (FQHCs). The bill permits DHCS to implement guidance without immediate rulemaking, and it conditions implementation on federal financial participation.
At a Glance
What It Does
Establishes pharmacist services as a Medi‑Cal benefit once CMS approval is obtained, creates a DHCS fee schedule, and fixes reimbursement: most pharmacist services at 85% of the physician fee schedule and advanced practice pharmacist services at 100% of that schedule. It enumerates covered services and allows DHCS to apply utilization controls and protocols.
Who It Affects
Community pharmacists and pharmacies that serve Medi‑Cal patients, advanced practice pharmacists, DHCS and county Medi‑Cal administrators, FQHCs that may bill for pharmacist services, and Medi‑Cal beneficiaries who access pharmacist-delivered clinical services.
Why It Matters
Shifts more clinical, reimbursable care into pharmacies—potentially expanding access to preventive and urgent services—while creating new Medicaid budget lines and operational requirements for billing, enrollment, utilization management, and federal approvals.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2571 transforms a set of pharmacist activities from practice permissions into billable Medi‑Cal services, but only if and when the federal Centers for Medicare & Medicaid Services (CMS) approves the changes and federal matching funds are available. The bill tasks DHCS with creating a fee schedule for pharmacist services and spells out two reimbursement tiers: a default 85% of the Medi‑Cal physician fee schedule for pharmacist services and full physician‑rate reimbursement for services delivered by advanced practice pharmacists.
The statute explicitly carves out MTM services and ties their treatment to another statutory section (14132.969), which suggests a separate rule set or rate treatment for MTM linked to specialty drugs.
The bill lists a defined package of covered services a pharmacist may provide and bill: furnishing travel medications, naloxone, self‑administered hormonal contraception, immunizations, tobacco cessation and nicotine replacement therapy, initiating and furnishing PrEP and PEP, and MTM in conjunction with dispensing certain specialty drugs. Those services are subject to DHCS protocols and utilization controls, meaning the department can set clinical criteria, documentation and prior authorization or limits on frequency or patient eligibility.Operationally, the statute requires pharmacists to enroll in Medi‑Cal as ordering, referring and prescribing providers before submitting claims, which creates a discrete credentialing and enrollment step that pharmacies and individual pharmacists must complete.
The bill also directs DHCS to seek federal approval via a state plan amendment to recognize pharmacists as billable providers at FQHCs, which could change how FQHCs assign revenue and staff pharmacists within the FQHC billing model.Finally, AB 2571 allows DHCS to implement the statutory scheme through all‑county letters, plan letters, and bulletins without immediate formal rulemaking, while retaining a direction to adopt regulations. The text conditions all of this on federal approvals and matching funds, so the practical rollout will hinge on CMS decisions and DHCS’s administrative choices about protocols, enrollment processes, and whether to apply utilization controls that may limit how often or in what circumstances services are paid.
The Five Things You Need to Know
DHCS must establish a fee schedule for pharmacist services and set most pharmacist reimbursement at 85% of the Medi‑Cal physician fee schedule.
Advanced practice pharmacist services are reimbursed at 100% of the physician fee schedule, and that full rate explicitly applies to MTM services referenced in Section 14132.969.
Covered, billable services include travel medications, naloxone, self‑administered hormonal contraception, immunizations, tobacco cessation plus nicotine replacement therapy, PrEP, PEP, and MTM tied to dispensing qualified specialty drugs.
Pharmacists must be enrolled as ordering, referring, and prescribing providers in Medi‑Cal before submitting any claims for pharmacist services.
Implementation is conditional on CMS approval and federal financial participation; DHCS must also seek a state plan amendment to recognize pharmacists as reimbursable providers at FQHCs.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishes benefit, fee schedule, and reimbursement tiers
This subsection makes pharmacist services a Medi‑Cal benefit, subject to CMS approval, and requires DHCS to create a fee schedule. It sets two reimbursement rules: standard pharmacist services at 85% of the physician fee schedule, and advanced practice pharmacist services (including MTM under 14132.969) at full physician rates. Practically, the dual-tier approach creates different payment signaling for credentialed advanced practice pharmacists versus other pharmacists and will affect contract rates, claims configuration, and provider enrollment categories in billing systems.
Enumerates covered pharmacist services and authorizes utilization controls
This provision enumerates the specific services DHCS will cover if implemented—ranging from naloxone distribution to immunizations, contraceptive furnishing, PrEP/PEP initiation, tobacco cessation, and MTM linked to specialty drugs. It also gives DHCS authority to constrain those services through protocols and utilization controls, meaning DHCS can impose clinical criteria, documentation requirements, frequency limits, and prior authorization processes to manage utilization and cost.
Enrollment requirement for billing
The bill requires pharmacists to be enrolled as ordering, referring, and prescribing providers in Medi‑Cal before submitting claims for these services. That creates a discrete administrative prerequisite: individual pharmacists (and possibly pharmacies) will need to complete Medi‑Cal provider enrollment steps, comply with provider agreement terms, and be reflected correctly in claims‑submission data to avoid denials.
Federal approvals and FQHC recognition
DHCS must seek necessary federal approvals before implementing the benefit and may only proceed to the extent federal financial participation is available. The statute also directs DHCS to pursue a state plan amendment to recognize pharmacists as reimbursable providers at federally qualified health centers—an important technical change that would allow FQHCs to bill for pharmacist‑delivered services under the clinic’s payment model rather than as separate pharmacy claims, altering internal revenue allocation and staffing decisions.
Administrative implementation and regulatory instruction
The statute permits DHCS to implement, interpret, or make specific the law through administrative guidance—such as all‑county letters, plan letters, and provider bulletins—without immediate formal rulemaking, though it also directs adoption of regulations by a date that appears inconsistent with the bill’s enactment. This gives DHCS fast‑track tools to operationalize billing and protocols but raises legal and timing questions about rulemaking and stakeholder notice.
MTM and specialty drug linkage
The bill references Section 14132.969 for the specific treatment of medication therapy management associated with qualified specialty drugs. That cross‑reference signals that MTM will be governed by separate or more detailed terms—potentially including eligibility, documentation, and different payment rules—which implementers will need to reconcile with the main fee schedule and utilization controls.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medi‑Cal beneficiaries who need point‑of‑care services: easier access to vaccinations, naloxone, contraception, PrEP/PEP, and tobacco cessation at pharmacies can lower barriers for patients who have trouble securing timely physician appointments.
- Community and retail pharmacists: creates a billing pathway and revenue stream for clinical services pharmacists already provide under scope‑of‑practice laws, potentially increasing pharmacy income and formalizing clinical roles.
- Advanced practice pharmacists: those with advanced practice authority will see a direct financial incentive because the bill pays them at full physician rates, improving returns on advanced training and credentialing.
- Federally qualified health centers (FQHCs): if DHCS secures the SPA, FQHCs can recognize pharmacist services within their clinic reimbursement models, enabling integrated care teams and possibly allowing FQHCs to expand service offerings without hiring additional physicians.
- Public health programs and payers focused on prevention: easier pharmacist billing for immunizations and naloxone could improve population health outcomes and reduce downstream emergency costs.
Who Bears the Cost
- California Medi‑Cal program (state budget and federal match): expanding billable provider types and services will create new Medicaid expenditures; DHCS will need to budget for state share and assess long‑term cost trajectories.
- DHCS and county Medi‑Cal administrators: DHCS must develop fee schedules, enrollment processes, protocols, utilization controls, billing instructions, and seek federal approvals—work that requires staff time and system changes.
- Pharmacies and pharmacists (administrative/compliance costs): enrollment as ordering/referring/prescribing providers, new documentation demands, prior authorization processes, and potential audits will add administrative burden and IT changes for claim submission.
- Managed care plans and other providers: plans may face pressure to adjust networks, negotiate rates, and update utilization management policies; physicians and clinics may experience shifts in service volumes for minor acute and preventive care.
Key Issues
The Core Tension
The central dilemma is straightforward: AB 2571 aims to expand timely, low‑barrier clinical care by paying pharmacists for services, but doing so risks increased Medi‑Cal spending, creates incentives that favor credentialed pharmacists, and places heavy implementation demands on DHCS—all while depending on CMS approval and complex FQHC billing changes that could slow or limit the intended access gains.
AB 2571 balances access goals against multiple operational and fiscal unknowns. The bill conditions implementation on CMS approval and federal financial participation; until CMS signs off, DHCS cannot pay for these services.
That dependency means the statutory reimbursement rules are aspirational until federal matching language and a state plan amendment are approved. The bill’s bifurcated reimbursement structure—85% for most pharmacists and 100% for advanced practice pharmacists—creates a clear financial incentive to seek advanced practice credentials, but it also complicates claims processing and could produce uneven access if only some pharmacists achieve the higher tier.
The statute authorizes DHCS to deploy utilization controls and to implement details via administrative guidance rather than waiting for formal regulations, which speeds rollout but invites implementation uncertainty and potential legal challenges. The bill text contains dated regulatory deadlines that precede enactment, which suggests drafting errors or conflicting timeframes that DHCS and counsel will need to reconcile.
Finally, linking MTM for specialty drugs to another statutory section signals a separate policy track for high‑cost therapies; absent explicit funding or clear utilization criteria, implementers will face difficult choices about which MTM encounters qualify for payment and how to prevent double‑billing or gaps in care coordination.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.